Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QDEL 
Quidel Corporation (QDEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: QDEL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $43.43
1 Year Target Price $43.43
| 3 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.46% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.94B USD | Price to earnings Ratio - | 1Y Target Price 43.43 |
Price to earnings Ratio - | 1Y Target Price 43.43 | ||
Volume (30-day avg) 8 | Beta 0.15 | 52 Weeks Range 22.05 - 49.45 | Updated Date 09/14/2025 |
52 Weeks Range 22.05 - 49.45 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -17.01% | Operating Margin (TTM) -0.73% |
Management Effectiveness
Return on Assets (TTM) 1.36% | Return on Equity (TTM) -15.64% |
Valuation
Trailing PE - | Forward PE 8.38 | Enterprise Value 4580916313 | Price to Sales(TTM) 0.71 |
Enterprise Value 4580916313 | Price to Sales(TTM) 0.71 | ||
Enterprise Value to Revenue 1.67 | Enterprise Value to EBITDA 21.7 | Shares Outstanding 67900496 | Shares Floating 62649044 |
Shares Outstanding 67900496 | Shares Floating 62649044 | ||
Percent Insiders 0.92 | Percent Institutions 117.99 |
Upturn AI SWOT
Quidel Corporation
Company Overview
History and Background
Quidel Corporation, founded in 1979, develops, manufactures, and markets diagnostic testing solutions for point-of-care and laboratory use. Initially focused on monoclonal antibody technology, it expanded into rapid diagnostic tests and molecular diagnostics through internal development and acquisitions.
Core Business Areas
- Rapid Immunoassay: Develops and manufactures rapid diagnostic tests for infectious diseases, cardiac biomarkers, and women's health.
- Molecular Diagnostics: Offers molecular diagnostic solutions for infectious diseases using real-time PCR technology.
- Specialty Products: Provides products for autoimmune and complement testing.
Leadership and Structure
The company is led by Douglas Bryant (CEO). The organizational structure includes departments for R&D, Manufacturing, Sales & Marketing, and Finance, operating under a board of directors.
Top Products and Market Share
Key Offerings
- Sofia 2 Fluorescent Immunoassay Analyzer: A point-of-care diagnostic system for influenza A and B, Strep A, RSV, and other respiratory illnesses. Competitors include Abbott (ABT) ID NOW, Roche (RHHBY) cobas Liat, and BD (BDX) Veritor. Market Share estimated around 10% of the POC market in 2023, but revenue from this product is hard to isolate since different tests can be done.
- Lyra Direct SARS-CoV-2 Assay: A real-time PCR assay for the detection of SARS-CoV-2. Market share has decreased since the height of the pandemic. Competitors include Roche (RHHBY), Thermo Fisher Scientific (TMO), and Abbott (ABT). Revenue from this product has declined significantly.
- Triage MeterPro: A cardiovascular and toxicology testing platform for hospital and physician office settings, including B-type natriuretic peptide (BNP) testing. Competitors include Abbott (ABT), Roche (RHHBY), and Siemens Healthineers (SHL). Market share is smaller than the main competitors, but revenue contribution is significant.
Market Dynamics
Industry Overview
The diagnostics industry is characterized by innovation in testing methodologies, increasing demand for point-of-care diagnostics, and regulatory scrutiny. The market is driven by aging populations, the prevalence of infectious diseases, and growing healthcare expenditure.
Positioning
Quidel Corporation is a mid-sized player in the diagnostics market, focusing on rapid and molecular diagnostics. It has a strong presence in point-of-care testing and aims to expand its market share through product innovation and strategic acquisitions.
Total Addressable Market (TAM)
The global in vitro diagnostics market is estimated to be around $90 billion USD. Quidel, as a mid-sized player, is positioned to capture a portion of the TAM through its established product lines and continued expansion into molecular diagnostics.
Upturn SWOT Analysis
Strengths
- Strong presence in point-of-care diagnostics
- Established distribution network
- Innovative product pipeline
- Proprietary technologies
Weaknesses
- Reliance on seasonal infectious disease testing (Flu)
- Smaller scale compared to larger competitors
- Fluctuating revenue based on pandemic surges
- Relatively low R&D investment compared to competitors
Opportunities
- Expanding into new geographic markets
- Developing new diagnostic tests for emerging diseases
- Strategic partnerships and acquisitions
- Growth in molecular diagnostics market
Threats
- Intense competition from larger diagnostic companies
- Changing regulatory landscape
- Economic downturn impacting healthcare spending
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Roche Holding AG (RHHBY)
- Thermo Fisher Scientific (TMO)
Competitive Landscape
Quidel Corporation is smaller than its main competitors, but it has a strong presence in point-of-care diagnostics. The competitive landscape is characterized by intense competition and continuous innovation.
Major Acquisitions
Ortho Clinical Diagnostics
- Year: 2022
- Acquisition Price (USD millions): 6000
- Strategic Rationale: Expanded product portfolio, broader geographic reach, and increased scale. This acquisition transformed Quidel into a larger, more diversified diagnostics company. Synergies included cross-selling opportunities, cost reductions, and R&D collaborations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was driven by acquisitions and increasing demand for rapid diagnostic tests, particularly during the COVID-19 pandemic. Post-pandemic growth has slowed significantly.
Future Projections: Analyst estimates suggest a return to moderate growth driven by new product launches and expansion into new markets, with projections of revenue stabilizing and potentially increasing over the next 3 years.
Recent Initiatives: Recent initiatives include the acquisition of Ortho Clinical Diagnostics (OCDX), focusing on synergies between the companies. Also, they are focusing on the development of new multiplex assays and expanding into new therapeutic areas.
Summary
Quidel Corporation has seen significant volatility in recent years. While it had exceptional growth during the COVID-19 pandemic, its revenue and profitability have since declined. The acquisition of Ortho Clinical Diagnostics offers potential for long-term growth, but the company faces significant integration challenges and fierce competition. Future success hinges on its ability to innovate, expand into new markets, and capitalize on synergies from the acquisition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Data is based on publicly available information and analyst estimates, which are subject to change. Market share estimates are approximate and may vary across different sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quidel Corporation
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 1991-02-01 | President, CEO & Director Mr. Brian J. Blaser | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6600 | Website https://www.quidelortho.com |
Full time employees 6600 | Website https://www.quidelortho.com | ||
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.